

MARCH 8—11, 2024 • VIRTUAL

# Update in Hematology and Medical Oncology

A Comprehensive Annual Update on the Diagnosis, Staging, and Management of Neoplastic Diseases with Expert Faculty



Memorial Sloan Kettering Cancer Center

# **Overview**

The Memorial Sloan Kettering 12<sup>th</sup> Annual Hematology and Medical Oncology Board Review is a four day course that provides an up-to-date and comprehensive review of the diagnosis, staging, and management of neoplastic disease, including solid tumor and hematologic oncology.

Lectures provided by expert faculty will focus on disease-specific topics in gastrointestinal, gynecologic, thoracic, head and neck, genitourinary, soft tissue and skin, central nervous system oncology, and hematologic oncology. Ample time will be provided at the conclusion of each presentation for an **interactive question-and-answer** session with the speakers.

Attendees of this course will receive access to an online syllabus, which includes select PDFs of presentations (slides) and video recordings of the lectures.

The target audience for this program is medical oncology professionals, including physicians, nurses, pharmacists, fellows, and residents. This course is designed to enable participants to effectively prepare for the American Board of Internal Medicine certification and recertification examinations in Hematology and Medical Oncology.

This course is set to be an **exclusively live virtual experience**. Detailed Zoom access and participation instructions will be provided to registrants prior to the start of the program.

#### LEARNING OBJECTIVES

At the conclusion of this 3.5-day course, learners will be able to:

- Define state-of-the-science in diagnosis, staging, and therapeutic management of solid tumor cancers and hematologic cancers.
- Discuss recent treatment advances in solid tumor and hematologic oncology and apply knowledge gained in modern clinical practice
- Prepare for ABIM examinations in medical oncology and hematology.

#### **ACCREDITATION**

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### **AMA Credit Designation Statement**

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **31.75 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

# **ABIM MOC Recognition Statement**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **31.75 Medical Knowledge MOC points** in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

#### MSK COURSE DIRECTORS



David H. Ilson, MD, PhD, FACP, FASCO Attending Physician, Member, Gastrointestinal Oncology Service; Professor of Medicine, Weill Cornell Medical College



Paul A. Hamlin, MD

Medical Director, David H. Koch Center for Cancer Care;
Attending Physician, Lymphoma Service;
Professor of Clinical Medicine,
Weill Cornell Medical College

#### MSK COURSE FACULTY

#### Ghassan K. Abou-Alfa, MD

Attending Physician, Gastrointestinal Oncology Service

#### Carol Aghajanian, MD

Chief, Gynecologic Medical Oncology Service; Avon Chair in Gynecologic Oncology Research

#### Lior Z. Braunstein, MD

Assistant Attending Radiation Oncologist, External Beam Radiotherapy Service

#### Noura J. Choudhury, MD

Assistant Attending Physician, Thoracic Oncology Service & Early Drug Development Service

#### Chau T. Dang, MD

Attending Physician, Breast Medicine Service

#### Lara A. Dunn, MD

Assistant Attending Physician, Head and Neck Oncology Service

#### Darren R. Feldman, MD

Chair, Quality Assurance; Section Head, Germ Cell Cancer; Associate Attending Physician, Genitourinary Oncology Service; Associate Professor of Medicine, Weill Cornell Medical College

#### Michael Foote, MD

Assistant Attending Physician, Gastrointestinal Oncology Service

#### Devika Gajria, MD

Medical Site Director, MSK Bergen; Assistant Attending Physician, Breast Medicine Service

#### Aaron D. Goldberg, MD, PhD

Assistant Attending Physician, Leukemia Service

#### Mrinal M. Gounder, MD

Associate Attending Physician, Sarcoma Medical Oncology Service & Early Drug Development Service; Physician Ambassador, India and Asia

#### Rachel N. Grisham, MD

Section Head, Ovarian Cancer; Director, Gynecologic Medical Oncology, MSK Westchester; Associate Attending Physician, Gynecologic Medical Oncology Service

#### Malin Hultcrantz, MD, PhD

Assistant Attending Physician, Myeloma Service; Assistant Professor of Medicine, Weill Cornell Medicine

#### Gopa Iyer, MD

Section Head, Bladder Cancer; Associate Attending Physician, Genitourinary Oncology Service & Early Drug Development Service

#### Thomas J. Kaley, MD

Vice Chair for Clinical Research, Department of Neurology; Chair, Institutional Review Board (IRB-C); Associate Attending Neuro-Oncologist

#### Robert Maki, MD, PhD

Attending Physician, Member, Sarcoma Medical Oncology Service & Early Drug Development Service; Professor of Medicine, Weill Cornell Medical College

#### Anita Mamtani, MD, FACS

Assistant Attending Surgeon, Breast Service

#### Simon Mantha, MD, MPH

Attending Physician, Hematology Service

#### Michael J. Mauro, MD

Director, Chronic Myeloid Leukemia Program; Attending Physician, Member, Leukemia Service; Professor of Medicine, Weill Cornell Medical College

#### Alison J. Moskowitz, MD

Associate Attending Physician, Lymphoma Service

#### Robert J. Motzer, MD

Section Head, Kidney Cancer; Jack and Dorothy Byrne Chair in Clinical Oncology; Attending Physician, Genitourinary Oncology Service

#### Eileen M. O'Reilly, MD

Winthrop Rockefeller Endowed Chair in Medical Oncology;
Co-Director, Medical Initiatives,
David M. Rubenstein Center for
Pancreatic Cancer Research;
Section Head, Hepatopancreaticobilary
& Neuroendocrine Cancers;
Attending Physician, Member,
Gastrointestinal Oncology Service;
Professor of Medicine,
Weill Cornell Medical College

#### Rekha Parameswaran, MD

Attending Physician, Hematology Service

#### Jae Park, MD

Chief, Cellular Therapy Service

#### Michael A. Postow, MD

Chief, Melanoma Service; Co-Director, Melanoma Disease Management Team

#### Raajit K. Rampal, MD, PhD

Director, Center for Hematologic Malignancies; Director, Myeloproliferative Neoplasms Program; Associate Attending, Leukemia Service

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

#### **Gregory J. Riely, MD, PhD**

Vice Chair, Clinical Research; Attending Physician, Thoracic Oncology Service

#### Leonard Saltz, MD

Executive Director for Clinical Value & Sustainability;
Head, Colorectal Oncology Section;
Attending Physician,
Gastrointestinal Oncology Service;
Professor of Medicine,
Weill Cornell Medical Center

#### Rachel Sanford, MD

Associate Attending Physician, Breast Medicine Service

#### Michael Scordo, MD

Assistant Attending Physician, Bone Marrow Transplant Service & Cellular Therapy Service

#### Susan K. Seo, MD

Director, Antibiotic Management Program; Attending Physician, Infectious Disease Service

#### Gunjan L. Shah, MD

Assistant Attending Physician, Bone Marrow Transplant Service & Cellular Therapy Service

#### Susan F. Slovin, MD, PhD

Associate Vice Chair, Academic Affairs; Attending Physician, Genitourinary Oncology Service & Cellular Therapy Service

#### Zsofia K. Stadler, MD

Clinical Director, Clinical Genetics Service; Associate Attending Physician, Clinical Genetics Service & Gastrointestinal Oncology Service

#### Eytan M. Stein, MD

Chief, Leukemia Service; Director, Program for Drug Development in Leukemia, Division of Hematologic Malignancies

#### Meghan C. Thompson, MD

Assistant Attending, Leukemia Service

#### Anna M. Varghese, MD

Assistant Attending Physician, Gastrointestinal Oncology Service

#### Cy R. Wilkins, MD

Assistant Attending Physician, Hematology Service; Assistant Professor of Clinical Medicine, Weill Cornell Medical College

#### Marjorie G. Zauderer, MD

Co-Director MSK Mesothelioma Program; Associate Attending Physician, Thoracic Oncology Service

#### Andrew D. Zelenetz, MD, PhD

Attending Physician, Lymphoma Service

#### Jeffrey Zwicker, MD

Chief, Hematology Service Professor of Medicine, Weill Cornell Medical College

#### **INVITED COURSE FACULTY**

#### Susanna Curtis, MD, PhD (They/Them)

Assistant Professor of Medicine, Hematology and Medical Oncology Assistant Director, The Mount Sinai Comprehensive Sickle Cell Program Icahn School of Medicine at Mount Sinai

# **Schedule**

#### FRIDAY, MARCH 8, 2024 • 9:00 AM — 6:00 PM EST

9:00 AM Attendee Zoom Sign On
 9:05 AM Welcome and Introduction
 David H. Ilson, MD, PhD, FACP, FASCO

#### **SOLID TUMOR**

9:15 AM **Colon Cancer** Leonard Saltz, MD 10:00 AM Melanoma Michael A. Postow, MD 10:45 AM **Prostate Cancer** Susan F. Slovin, MD, PhD 11:30 AM **Kidney Cancer** Robert J. Motzer, MD 12:15 PM Mesothelioma Marjorie G. Zauderer, MD Lunch Break 12:30 PM 1:15 PM **Urothelial Cancer** Gopa Iyer, MD 2:00 PM **Testis Cancer** Darren R. Feldman, MD 2:45 PM **Uterine, Cervix, and Other GYN Cancers** Carol Aghajanian, MD 3:30 PM Break 3:45 PM **Ovarian Cancer** Rachel N. Grisham, MD 4:30 PM **Breast Cancer: Surgery** Anita Mamtani, MD, FACS 5:00 PM **Breast Cancer: Radiation Therapy** Lior Z. Braunstein, MD Genetics 5:30 PM Zsofia K. Stadler, MD 6:00 PM **Closing Remarks and Adjournment** 

David H. Ilson, MD, PhD, FACP, FASCO

## **SATURDAY, MARCH 9, 2024** • 6:50 AM — 6:00 PM EST

6:50 AM	Attendee Zoom Sign On
6:55 AM	Day 2 Introduction
	David H. Ilson, MD, PhD, FACP, FASCO
7:00 am	Small Cell Lung Cancer
	Noura J. Choudhury, MD
7:30 ам	Triple Negative Breast Cancer:
	(Neo)adjuvant and Metastatic Rachel Sanford, MD
8:00 AM	HER2 Positive Breast Cancer:
0.00 AM	(Neo)adjuvant and Metastatic
	Chau T. Dang, MD
9:00 AM	Hormone Receptor Positive Breast Cancer:
	(Neo)adjuvant and Metastatic
	Devika Gajria, MD
10:00 am	Carcinoma of Unknown Primary
10:30 am	Anna M. Varghese, MD  Break
10:45 AM	
10:45 AM	<b>Hepatocellular Cancer and Cholangiocarcinoma</b> Ghassan K. Abou-Alfa, MD
11:30 ам	Pancreatic and Neuroendocrine Cancer Eileen M. O'Reilly, MD
12:15 PM	Lunch Break
1:00 PM	Non Small Cell Lung Cancer Gregory J. Riely, MD, PhD
2:00 рм	Head & Neck, Thyroid, and Non-Melanoma Skin Cancer
	Lara A. Dunn, MD
3:00 рм	Anal and Rectal Cancer
	Michael Foote, MD
3:30 PM	Break
3:45 рм	<b>Esophageal and Gastric Cancer</b> David H. Ilson, MD, PhD, FACP, FASCO
4:30 PM	CNS Tumors
	Thomas J. Kaley, MD
5:00 рм	Sarcoma Robert Maki, MD, PhD
5:30 рм	Infectious Disease
	Susan K. Seo, MD
6:00 рм	Closing Remarks and Adjournment

David H. Ilson, MD, PhD, FACP, FASCO

# SUNDAY, MARCH 10, 2024 $\, \bullet \, \, 6:50 \, \text{Am} - 6:00 \, \text{PM} \, \text{EDT} \,$

6:50 ам	Attendee Zoom Sign On
6:55 ам	<b>Day 3 Introduction</b> Paul A. Hamlin, MD
7:00 am	<b>Pharmacology</b> Mrinal M. Gounder, MD
9:00 AM	Break
<b>MALIGNA</b>	NT HEMATOLOGY
9:10 am	<b>Acute Myeloid Leukemia (AML)</b> Eytan M. Stein, MD
9:50 am	<b>Low-Grade Non-Hodgkin Lymphoma (NHL)</b> Andrew D. Zelenetz, MD, PhD
10:30 ам	Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL) Meghan C. Thompson, MD
11:10 ам	Diffuse Large B-Cell Lymphoma (DLBCL) Mantle Cell Lymphoma (MCL) Burkitt Lymphoma (BL) Paul A. Hamlin, MD
12:10 рм	Lunch Break
12:40 рм	Hodgkin Lymphoma (HL) / T Cell Alison J. Moskowitz, MD
1:40 рм	Auto / Allo Gunjan L. Shah, MD
2:20 РМ	CAR T Cells Michael Scordo, MD
2:50 AM	<b>Acute Lymphocytic Leukemia (ALL)</b> Jae Park, MD
3:20 рм	Break
3:40 рм	<b>Myeloproliferative Neoplasms (MPN)</b> Raajit K. Rampal, MD, PhD
4:05 рм	<b>Myelodysplastic (MDS)</b> Aaron D. Goldberg, MD, PhD
4:30 рм	<b>Chronic Myelogenous Leukemia (CML)</b> Michael J. Mauro, MD
5:00 рм	<b>Myeloma / Amyloid</b> Malin Hultcrantz, MD, PhD
6:00 рм	<b>Closing Remarks and Adjournment</b> Paul A. Hamlin, MD

## MONDAY, MARCH 11, 2024 • 7:50 AM — 12:00 PM EDT

7:50 AM Attendee Zoom Sign On

## **BENIGN HEMATOLOGY**

8:00 am	<b>Day 4 Introduction</b> Paul A. Hamlin, MD
8:05 AM	<b>Approach to The Bleeding Patient</b> Rekha Paramewaran, MD
8:50 AM	The Role of the New Direct Oral Anticoagulants in Practice Simon Mantha, MD, MPH
9:50 AM	Clotting in Cancer Jeffrey Zwicker, MD
10:30 ам	<b>Thrombocytopenia, ITP, and Beyond</b> Cy R. Wilkins, MD
11:00 AM	<b>Sickle Cell Disease, Thalassemia</b> Susanna Curtis, MD, PhD (They/Them)
12:00 рм	<b>Closing Remarks and Adjournment</b> Paul A. Hamlin, MD

Faculty will be available at the conclusion of each presentation for a live, interactive Q&A with attendees.

msk.org/HemOncUpdate



#### **REGISTER ONLINE AT**

# msk.org/HemOncUpdate

#### REGISTRATION FEES

Physicians (MDs, PhDs, and DOs) \$1,650

APPs, Residents, Fellows, Nurses, and Other Healthcare Providers

Industry Professionals\* \$2,885

MSK Employees Complimentary

MSK Alumni and MSK Cancer Alliance Members: A discounted registration rate is offered to MSK Alumni and MSK Cancer Alliance members for all CME programs at MSK. Please visit the course website for additional information.

\*Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

#### CANCELL ATION POLICY

If you wish to cancel your participation in this course, you must email cme@mskcc.org at least seven (7) days prior to the start of the course, and your refund will be subject to a \$25 administrative fee. Cancellations or no-shows within seven (7) days of the course are not eligible for a refund. Please note that if it has been more than 120 days since payment was processed, a W9 form must be submitted in order process your refund and your refund will be issued in the form of a check payment. Refunds are not subject to tax. You may substitute another registrant in your place at any time by contacting me@mskcc.org with the appropriate information.

MSK CME reserves the right to cancel or postpone any course due to unforeseen circumstances. In the unlikely event we must cancel or postpone this course, you will be notified via email from MSK CME (me@mskcc.org). A full refund will be issued for your registration. MSK CME is not responsible for any related costs, charges, or expenses to participants, including fees incurred by airline/travel/lodging agencies.

